The EHEC disaster – opportunities for the early treatment of acutely ill patients using an „old“ natural preparation.

Reports on the therapeutic options for the treatment of hemorrhagic diarrhoea and the prophylaxis of life-threatening complications like HUS as a result of the infection with „Killer Coli“, as enterohaemorrhagic Escherichia coli (EHEC) is termed sometimes, are often evidence of a degree of uncertainty and above all a lack of knowledge with regards to proven and tested therapeutic treatments.

In the context of the epidemic of severe EHEC cases which occured in Bavaria, Germany in the 1990s, we carried out a placebo-controlled clinical study of a colostrum preparation (Lactobin®) on 30 acutely ill children at the University Hospital Wuerzburg (I.Huppertz et al - J Pediatr Gastroenterol Nutr 1999; 29:452-456). The patients treated with Lactobin® experienced a normalisation of the encreased defecation rates within a shortest possible time period (statistically highly relevant compared with the placebo group) and an increased elimination of EHEC. Even though preliminary investigations indicate that the current epidemic deals with a new variant of EHEC, a treatment attempt with40g Lactobin® (now Lactobin N®) per day would be recommendable in suspected cases of EHEC infection (severe diarrhoea lasting more than 24 hours with more than 4 possibly hemorrhagic stools per day) on the basis of the data from Wuerzburg.

Any risk to provoke HUS through this regimen (as this is discussed in the medicinal literature concerning the use of antibiotics in EHEC infected patients), the preparation is well-tolerated (exception: lactose intolerance) and can be taken over longer periods.
(Manufacturer: Dr Wolz Zell GmbH in Geisenheim, info@wolz.de).

MD Reinhard Lissner

MD R. Lissner

Dr. Wolz Zell GmbH
Marienthaler Str. 3
65366 Geisenheim
Germany

Press contact: Herr Dr. Oldhaver
Fon: +49 (0)6722 - 5610 - 0
Fax: +49 (0)6722 - 5610 – 20
Email: info@wolz.de

This release was published on openPR.